
Feature|Videos|April 25, 2024
2024 AUA preview: Dr. Elterman on key research in BPH
Author(s)Urology Times staff
Dean S. Elterman, MD, MSc, FRCSC, highlights several studies in BPH being presented at the 2024 AUA Annual Meeting.
Advertisement
In this video, Dean S. Elterman, MD, MSc, FRCSC, highlights 4 studies in benign prostatic hyperplasia (BPH) that will be presented at the upcoming 2024 American Urological Association (AUA) Annual Meeting, which will take place on May 3 – 6 in San Antonio, Texas. Elterman is a urologist at the University of Toronto in Canada.
Elterman previewed the following abstracts:
- MP46-02 (Roehrborn et al): The Early Patient Experience Following Treatment with PUL and WVTT, Two Contemporary MISTs for BPH: Preliminary Results from the CLEAR Study
- MP06-15 (Elliott et al): The Optilume® Drug Coated Balloon for recurrent anterior urethral strictures: ROBUST III study 4-year interim results
- MP46-04 (Cerrato et al): Rezum for BPH: results from a large retrospective multicenter study
- MP27-01 (Gilling et al): 24-Month Outcomes from the ZEST Pilot studies of the Zenflow Spring System for the Treatment of Benign Prostatic Hyperplasia (BPH)
Advertisement
Related to this article

Muhammed A. Moukhtar Hammad, MBBCh, MSc, discusses real-world trends in baseline erectile dysfunction treatment across AUA sections before minimally invasive BPH procedures.

Earlier genetic testing in men with very low sperm counts may spare unnecessary testing or surgery, according to Ronald Anglade, MD.

Vignesh Packiam, MD, discusses optimizing BCG treatment in high-risk NMIBC, including patient selection for combination immunotherapy and treatment-related trade-offs.

VOLGA results raise the question of treatment de-intensification in perioperative MIBC care, according to Suzanne B. Merrill, MD, FACS.

Patient goals, disease features, and response to prior therapy guide treatment choices across high-risk NMIBC, according to Suzanne B. Merrill, MD, FACS.

Suzanne B. Merrill, MD, discusses emerging perioperative approaches in MIBC and the potential for more personalized treatment selection based on disease characteristics.

BCG monotherapy and a high-quality TURBT remain the foundation for BCG-naive high-risk NMIBC, according to Vignesh T. Packiam, MD.
Advertisement
Advertisement
Trending on Urology Times
1
Treatment interruptions in prostate cancer: Balancing PSA kinetics and quality of life
2
Cretostimogene reduces recurrence risk by 68% in phase 3 PIVOT-006 trial in NMIBC
3
Rethinking Testosterone Therapy After the FDA Label Revisions
4
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
5




